Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free ABDX Stock Alerts

Abingdon Health (ABDX) Competitors

Abingdon Health logo
GBX 10.50 +0.22 (+2.17%)
As of 09:56 AM Eastern
Compare

ABDX vs. GDR, YGEN, AGL, GENI, and PRM

Should you buy Abingdon Health stock or one of its competitors? MarketBeat compares Abingdon Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abingdon Health include genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), GENinCode (GENI), and Proteome Sciences (PRM). These companies are all part of the "diagnostics & research" industry.

How does Abingdon Health compare to genedrive?

genedrive (LON:GDR) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Abingdon Health has higher revenue and earnings than genedrive. Abingdon Health is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
genedrive£929K22.47-£21.22M-£0.79N/A
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A

Abingdon Health has a net margin of -33.88% compared to genedrive's net margin of -500.75%. Abingdon Health's return on equity of -55.91% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
genedrive-500.75% -1,044.57% -74.09%
Abingdon Health -33.88%-55.91%-17.93%

0.1% of genedrive shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 29.0% of genedrive shares are owned by insiders. Comparatively, 8.0% of Abingdon Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, genedrive had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Abingdon Health. genedrive's average media sentiment score of 0.64 beat Abingdon Health's score of 0.00 indicating that genedrive is being referred to more favorably in the media.

Company Overall Sentiment
genedrive Positive
Abingdon Health Neutral

genedrive has a beta of 1.024, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Summary

genedrive beats Abingdon Health on 7 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to Yourgene Health?

Abingdon Health (LON:ABDX) and Yourgene Health (LON:YGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Yourgene Health has a net margin of -27.55% compared to Abingdon Health's net margin of -33.88%. Yourgene Health's return on equity of -27.06% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
Yourgene Health -27.55%-27.06%-6.71%

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled Yourgene Health'saverage media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
Yourgene Health Neutral

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 23.3% of Yourgene Health shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by insiders. Comparatively, 64.4% of Yourgene Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Abingdon Health has higher earnings, but lower revenue than Yourgene Health. Abingdon Health is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A

Abingdon Health has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Summary

Yourgene Health beats Abingdon Health on 8 of the 10 factors compared between the two stocks.

How does Abingdon Health compare to ANGLE?

Abingdon Health (LON:ABDX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Abingdon Health has a net margin of -33.88% compared to ANGLE's net margin of -1,444.04%. Abingdon Health's return on equity of -55.91% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
ANGLE -1,444.04%-191.36%-29.89%

Abingdon Health has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

In the previous week, ANGLE had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Abingdon Health. ANGLE's average media sentiment score of 0.67 beat Abingdon Health's score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.

Company Overall Sentiment
Abingdon Health Neutral
ANGLE Positive

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 8.0% of Abingdon Health shares are held by insiders. Comparatively, 2.7% of ANGLE shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A
ANGLE£2.62M2.89-£21.76M-£4.80N/A

Summary

Abingdon Health beats ANGLE on 7 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to GENinCode?

GENinCode (LON:GENI) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

4.5% of GENinCode shares are held by institutional investors. Comparatively, 3.7% of Abingdon Health shares are held by institutional investors. 8.7% of GENinCode shares are held by insiders. Comparatively, 8.0% of Abingdon Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Abingdon Health has a net margin of -33.88% compared to GENinCode's net margin of -185.47%. Abingdon Health's return on equity of -55.91% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-185.47% -409.40% -63.99%
Abingdon Health -33.88%-55.91%-17.93%

GENinCode has a beta of 0.593, indicating that its share price is 41% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

In the previous week, GENinCode had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for GENinCode and 0 mentions for Abingdon Health. GENinCode's average media sentiment score of 1.27 beat Abingdon Health's score of 0.00 indicating that GENinCode is being referred to more favorably in the media.

Company Overall Sentiment
GENinCode Positive
Abingdon Health Neutral

Abingdon Health has higher revenue and earnings than GENinCode. Abingdon Health is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£3.08M2.24-£6.10M-£2.08N/A
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A

Summary

Abingdon Health beats GENinCode on 7 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Proteome Sciences had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for Abingdon Health. Proteome Sciences' average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Abingdon Health Neutral

Abingdon Health has higher revenue and earnings than Proteome Sciences. Abingdon Health is trading at a lower price-to-earnings ratio than Proteome Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.57-£4.08M-£1.04N/A
Abingdon Health£9.57M2.75-£796.37K-£0.81N/A

Proteome Sciences has a beta of 0.148, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by company insiders. Comparatively, 8.0% of Abingdon Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abingdon Health has a net margin of -33.88% compared to Proteome Sciences' net margin of -81.50%. Proteome Sciences' return on equity of 33.80% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Abingdon Health -33.88%-55.91%-17.93%

Summary

Abingdon Health beats Proteome Sciences on 8 of the 12 factors compared between the two stocks.

Get Abingdon Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABDX vs. The Competition

Export
MetricAbingdon HealthDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£26.36M£645.27M£6.87B£2.82B
Dividend YieldN/A3.37%2.66%6.15%
P/E Ratio-12.9678.3327.74368.94
Price / Sales2.75619.15528.4786,051.49
Price / Cash2.2511.4229.6527.87
Price / Book14.433.2111.107.86
Net Income-£796.37K£334.07B£3.57B£5.89B
7 Day Performance3.30%1.72%2.22%0.91%
1 Month Performance-16.00%-1.18%7.13%-0.41%
1 Year Performance50.00%6.49%33.77%70.55%

Abingdon Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABDX
Abingdon Health
N/AGBX 10.50
+2.2%		N/A+46.8%£26.36M£9.57MN/A84
GDR
genedrive
N/AGBX 1.28
-1.8%		N/A-6.0%£20.50M£929KN/A43
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-62.4%£7.58M£2.62MN/A650
GENI
GENinCode
N/AGBX 0.94
+4.4%		N/A-58.4%£6.82M£2.91MN/A2,300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:ABDX) was last updated on 7/6/2026 by MarketBeat.com Staff.
From Our Partners
Elon Musk on His New Invention: “An Infinite Money Glitch.”
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...
Brownstone Research | Sponsoredtc pixel
He’s Back. And He’s About to Act
The U.S. government holds 8,133 tonnes of gold valued at just $42.22 an ounce on its books - while gold trades...
Priority Gold | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel